Turn Biotechnologies, a pioneer in epigenetic reprogramming, announced the acquisition of the company's groundbreaking ARMMs (ARRDC1-mediated microvesicles) technology, significantly expanding the number of organs, tissues and cells that can be safely and precisely treated with the company's epigenetic therapies.

Turn Bio has acquired the license for the ARMMs delivery technology from Harvard University , along with all related assets from Vesigen Therapeutics of Cambridge, Massachusetts.

The addition of ARMMs to the company's eTurna® LNP delivery platform expands the reach of Turn Bio's ERA® technology, which uses mRNA to produce proteins that translate the cellular epigenome to restore function and combat age-related diseases.

The license and associated intellectual property will enable Turn Bio to accelerate the progress of drug candidates in its pipeline for ophthalmology and immune cell rejuvenation. ARMMs will allow the company to advance these candidates alongside TRN-001, a skin rejuvenation therapy leveraging the company's eTurna platform.

"ARMMs technology is central to Turn Bio's mission to harness the power of epigenetics and shape what it can mean for the future of aging healthcare," said Anja Krammer , the company's CEO. "This will allow us to deliver our therapies with exact precision when needed.

"Equally exciting is that this technology allows us to deliver larger and more diverse cargoes, including proteins and gene and epigenetic editors," she said. "This unprecedented delivery capability means Turn Bio will help define the future of regenerative medicine."

This ARMMs technology has attracted the attention of top investors, including Bayer Healthcare LLC, Morningside Group Ltd. and Alexandria Ventures.